SEC Comment Letter 0000000000-23-001770 to Sibannac, Inc. (SNNC) (CIK 0001313938) (SNNC)
Sibannac, Inc. (SNNC) (CIK 0001313938)
Date: Feb. 22, 2023 · CIK: 0001313938 · Accession: 0000000000-23-001770
AI Filing Summary & Sentiment
File numbers found in text: 024-12159
Letter
United States securities and exchange commission logo February 22, 2023 David Mersky Chief Executive Officer Sibannac, Inc. 9535 E. Doubletree Ranch Rd., Ste 120 Scottsdale, AZ 85258 Re:Sibannac, Inc. Offering Statement on Form 1-A Filed February 17, 2023 File No. 024-12159 Dear David Mersky: This is to advise you that we do not intend to review your offering statement. We will consider qualifying your offering statement at your request. In connection with your request, please confirm in writing that at least one state has advised you that it is prepared to qualify or register your offering. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Carl Ranno, Esq.
Show Raw Text
United States securities and exchange commission logo
February 22, 2023
David Mersky
Chief Executive Officer
Sibannac, Inc.
9535 E. Doubletree Ranch Rd., Ste 120
Scottsdale, AZ 85258
Re:Sibannac, Inc.
Offering Statement on Form 1-A
Filed February 17, 2023
File No. 024-12159
Dear David Mersky:
This is to advise you that we do not intend to review your offering statement.
We will consider qualifying your offering statement at your request. In connection with
your request, please confirm in writing that at least one state has advised you that it is prepared
to qualify or register your offering. If a participant in your offering is required to clear its
compensation arrangements with FINRA, please have FINRA advise us that it has no objections
to the compensation arrangements prior to qualification.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Carl Ranno, Esq.